San Diego, California — November 24, 2025 — Leads & Copy — Skye Bioscience, Inc. (NASDAQ: SKYE), a clinical-stage biotechnology company, will participate in several upcoming investment conferences.
Skye, which focuses on developing new therapeutic pathways for obesity and other metabolic health disorders, will be present at the following events:
- Citi Global Healthcare Conference in Miami, with 1×1 meetings on December 2.
- Evercore Annual Healthcare Conference in Coral Gables, featuring a fireside chat on December 3 at 12:55 pm ET, and 1×1 meetings.
- Piper Sandler Annual Healthcare Conference in New York, including a fireside chat on December 4 at 11:30 am ET, and 1×1 meetings.
Webcasts of available sessions will be accessible on Skye’s website.
Skye’s strategy involves leveraging biologic targets with human proof of mechanism to develop potential first-in-class therapeutics, emphasizing clinical and commercial differentiation. Currently, Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. The study also assesses the combination of nimacimab and a GLP-1R agonist (Wegovy®).
For further information, visit Skye’s website and connect with them on X and LinkedIn.
Investor & Media Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Source: Skye Bioscience, Inc.
